HNN3.0
Register
Register
Register

Project cooperationUpdated on 23 April 2026

LNP development

CEO at Anthelos KFT

Szeged, Hungary

About

Anthelos expertise in LNPs covers microfluidics design and production with its flexible nanoparticle generating system, LNP characterization, stability tests with its scanning nanoparticle tracking analysis system for tailored LNP formulations to optimize drug delivery for the clients’ specific therapeutic needs.

Efficiency and toxicity studies can be performed by Anthelos in primary immune cells (B-, T-cells), liver and DC cells with plate imaging and FACS analysis. Cell-type specific transfection efficiency analysis of different tissues can be done with confocal fluorescent microscopy. Anthelos applies in vivo imaging by using the company’s custom tailored in vivo imaging system with superior sensitivity for full body imaging, tissue distribution, organ- and cancer-specific targeting projects.

Anthelos is developing novel lipids and lipid additives to enhance LNP effectivity and specific targeting to liver and extrahepatic organs.

Organisation

Anthelos KFT

Company (SME)

Szeged, Hungary

Similar opportunities

  • Project cooperation

    Research tools and solutions for lipid nanoparticles (LNPs)

    Laszlo Puskas

    CEO at Anthelos KFT

    Szeged, Hungary

  • Project cooperation

    LNP delivery with barcoded mRNA

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

    Filip Van Nieuwerburgh

    Professor at Ghent University

    Ghent, Belgium

  • Project cooperation

    Medical education collaboration

    • Consortium/Coordinator seeks Partners
    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Luca Takács

    Founder and CEO at LNP Academy

    Budapest, Hungary